{"classes":[{"categories":[{"measurements":[{"comment":"Values could not be estimated due to limited amount of observed follow-up time.","groupId":"OG000","lowerLimit":"14.5","upperLimit":"NA","value":"NA"},{"groupId":"OG001","lowerLimit":"2.9","upperLimit":"12.2","value":"6.0"},{"groupId":"OG002","lowerLimit":"7.9","upperLimit":"18.7","value":"13.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"}],"units":"Participants"}],"description":"Overall survival is defined as the interval of time (in months) between the date of first dose and the date of death due to any cause. The median overall survival is presented along with 95% confidence interval. Confidence intervals were estimated using Brookmeyer Crowley method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants were administered twice daily (BID) oral dose of 20 mg GSK525762.","id":"OG000","title":"Part 1: GSK525762 20 mg BID"},{"description":"Participants were administered twice daily oral dose of 30 mg GSK525762.","id":"OG001","title":"Part 1: GSK525762 30 mg BID"},{"description":"Participants were administered twice daily oral dose of 40 mg GSK525762.","id":"OG002","title":"Part 1: GSK525762 40 mg BID"}],"paramType":"MEDIAN","populationDescription":"All Treated Population","reportingStatus":"POSTED","timeFrame":"Median of 1.41 months of drug exposure","title":"Overall Survival-Part 1 BID","type":"SECONDARY","unitOfMeasure":"Months"}